PTHrP类似物影响绝经后妇女骨质疏松症的骨代谢  

PTHrP Analogues Affect Bone Metabolism in Postmenopausal Women with Osteoporosis

作　　者：赵研 许慧宁[1] 

机构地区：[1]青海大学附属医院老年科,青海 西宁

出　　处：《临床医学进展》2022年第5期4127-4131,共5页Advances in Clinical Medicine

摘　　要：骨质疏松症和脆性骨折是相关联的健康问题,其致残患者较其他慢性病患者住院时间长,相关的医疗费用正以惊人的速度递增。甲状旁腺激素和甲状旁腺激素相关蛋白类似物,无论是作为单一疗法、与抗再吸收剂联合使用,还是与抗再吸收剂联用,都可能在骨质疏松症管理中发挥越来越大的作用。对于绝经后妇女的临床评估骨质减少、早期干预及管理是必要且重要的,将对PTHrP类似物阿巴洛肽在骨质疏松症的作用做一综述。Osteoporosis and fragility fractures are associated health problems, and their disabled patients have longer hospital stays than other patients with chronic diseases, and the related medical costs are increasing at an alarming rate. Parathyroid hormone and parathyroid hormone-related protein analogues, whether as monotherapy, in combination with anti-resorptive agents, or in combination with anti-resorptive agents, are likely to play an increasing role in osteoporosis management. Clinical evaluation of osteopenia, early intervention and management in postmenopausal women is necessary and important, and the role of the PTHrP analogue abalopeptide in osteoporosis will be reviewed.

关 键 词：绝经后骨质疏松症 Abaloparatide Teriprapeptide PTHrP类似物 骨代谢 

分 类 号：R580[医药卫生—内分泌]